A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients

Colorectal Cancer Clinical Trial

Official title:

A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02869269
• Other study ID #: KUH1160096
• Status: Completed
• Phase: N/A
• First received: July 15, 2016
• Last updated: January 26, 2018
• Start date: October 2015
• Est. completion date: October 2016

Study information

• Verified date: January 2018
• Source: Konkuk University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Previous studies have shown that colorectal cancer patients' prognosis and overall survival was related with immune cell expression in patients' tissue. However, the circulating immune cell activity changes in patients' blood has few studies. The purpose of this study is to analyze the variation of circulating immune cell activity in colorectal patients' blood which is classed as clinical staging.

Description:

The patients were classed as clinical staging

1. Early (stage1+2) and Late(stage3+4)

2. regional lymph node metastasis

3. Distant metastasis

4. TNM stage

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: October 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• patient who was planned to undergo colorectal cancer surgery.

Exclusion Criteria:

• age < 20 years old

• history of hypersensitivity reaction in propofol or sevoflurane

• history of previous cancer

• patient with ongoing inflammation

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Device:
• Early stage
patients who classed as clinical stage 1 and 2
• Late stage
patients who classed as clinical stage 3 and 4

Locations

Country	Name	City	State
Korea, Republic of	Konkuk University Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Konkuk University Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	CD4 and Treg cell activity and change of percentage of CD39 and CD73	change of expression level of CD4 and Treg cell activity and change of percentage of CD39 and CD73(0~100 %)	preoperative time
Primary	Circulating helper T cell activity	change of expression level of T cell (0~100 %)	preoperative time
Secondary	Cytotoxic T cell and natural killer cell activity	change of expression level Cytotoxic T cell and natural killer cell(0~100 %)from 0 to 100)	preoperative time